Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutex Health Inc. filings document the reporting obligations of a healthcare services and operations company with hospital, population health management and real estate-related activities. Recent Form 8-K reports furnish operating and financial results, including revenue, hospital division performance, earnings measures and cash flow, and disclose other corporate events tied to registration statements and auditor consents.
Proxy and annual-meeting filings cover board elections, advisory executive compensation votes, auditor ratification, common stock voting results and related governance disclosures. These documents also frame the company's capital actions, including common stock repurchase authorizations, within its public-company reporting record.
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported routine equity compensation activity. She exercised restricted stock units that convert into common stock on a one-for-one basis, resulting in the issuance of 2,084 shares of common stock, of which 776 shares were delivered to cover tax withholding obligations.
After these transactions, Montgomery directly held 2,679 shares of common stock. She was also granted 1,525 restricted stock units on March 11, 2026, scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. director Kelvin Spears reported compensation-related stock activity. He received 183 shares of common stock upon vesting of previously granted restricted stock units, with 82 of those shares withheld to cover tax obligations, leaving a net 101 new shares and bringing his direct common stock holdings to 32,127 shares.
He was also granted 116 new restricted stock units that each convert into one share of common stock and are scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. These transactions are routine equity compensation events rather than open-market purchases or sales.
Nutex Health Inc. Chief Medical Officer Michael L. Chang reported equity compensation and related tax withholding transactions. On March 10, 2026, he was granted 1,936 restricted stock units (RSUs), which will vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. A related entry shows 2,084 common shares issued subsequent to vesting, with 769 shares delivered to cover tax withholding obligations at an indicated value of $86.2224 per share, a non‑market disposition that does not represent an open‑market sale. Following these transactions, Michael Chang PLLC directly holds 82,356 common shares, and Dr. Chang directly owns an additional 984 shares, reflecting ongoing equity alignment through both direct and indirect holdings.
Nutex Health Inc. president Warren Hosseinion reported routine equity compensation activity. He exercised 3,656 restricted stock units, which convert into common stock on a one-for-one basis, and received 6,293 common shares upon vesting. Of those shares, 3,274 were delivered at a price of 86.2224 per share to cover tax withholding obligations. Following these transactions, he holds 7,513 shares of common stock directly and 15,739 restricted stock units that remain outstanding and unexercised, which are scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. CEO Thomas T. Vo reported routine equity compensation activity involving restricted stock units and common shares. Previously granted RSUs converted into 8,334 shares of common stock, and 3,017 of those shares were delivered to satisfy tax withholding obligations rather than sold in an open-market trade.
After these transactions, entities he owns and controls held 1,843,196 common shares, and his direct holdings included 19,524 restricted stock units. He was also granted 4,841 new RSUs that vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. Chief Financial Officer Jon Christian Bates reported compensation-related equity activity. He acquired 2,667 shares of common stock through a derivative exercise, bringing his direct common stock holdings to 8,305 shares. He was also granted 1,694 restricted stock units, which convert into common stock on a one-for-one basis and vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, increasing his restricted stock unit balance to 5,527 units. These transactions reflect equity compensation and derivative exercises, not open-market buying or selling.
Nutex Health, Inc. ownership disclosure: Pertento Partners LLP, Pertento Advisors LLC and Eduardo Marques each report 361,988 shares of Common Stock, 5.2% of the class, as reported in the Schedule 13G. The filing states these securities are directly owned by advisory clients of Pertento Partners LLP. The reporting persons signed a Joint Filing Agreement.
Nutex Health reported strong growth for 2025 while highlighting its reliance on arbitration-related revenue and a weaker fourth quarter. For the year ended December 31, 2025, total revenue rose to $875.3 million from $479.9 million, driven mainly by the hospital division, which generated $844.2 million. About $527.8 million of hospital revenue, roughly 63%, came from higher acuity claims and success in the Independent Dispute Resolution process, where the company reports prevailing in over 85% of determinations with an average collection rate above 85%.
Full-year net income attributable to Nutex Health increased to $70.8 million, including $117.0 million of non‑cash stock‑based compensation tied to earn‑out shares. Diluted EPS was $10.48. EBITDA attributable to Nutex Health was $168.6 million, and Adjusted EBITDA rose to $259.6 million. Net cash from operating activities totaled $248.1 million. As of year‑end, the company reported total assets of $918.5 million, including cash and cash equivalents of $185.6 million and long‑term debt, net, of $29.2 million.
Fourth quarter 2025 revenue fell to $151.7 million from $257.6 million a year earlier, largely due to a one‑time $55.0 million cumulative true‑up for ineligible arbitration claims and the absence of $69.0 million of arbitration revenue that benefited the prior‑year quarter. Adjusted EBITDA for the quarter declined to $16.6 million. After normalizing for these items, the company states that fourth quarter 2025 revenue would have exceeded the prior‑year period. Hospital division visits grew 11.8% for the full year to 188,279, with a 6.1% increase in the fourth quarter. Nutex also indicated it is launching a second stock repurchase program.
Nutex Health Inc. is a physician-led healthcare company that runs 26 micro-hospitals in 12 states, a population health management arm built around independent physician associations, and a real estate division that owns or consolidates certain hospital properties. It employs 944 full-time staff and works with thousands of physicians.
For the year ended December 31, 2025, hospital division revenue was 844,162 and population health management revenue was 31,095 (both in thousands), for total revenue of 875,257 (in thousands), reflecting rapid growth over 2024 and 2023. The business depends heavily on out-of-network billing and the federal No Surprises Act arbitration process, where Nutex uses a third-party expert to arbitrate disputed claims.
The company plans to open four new hospital facilities in 2026 and launch additional IPAs around its existing micro-hospitals, while acknowledging significant regulatory, reimbursement, arbitration-cost, litigation, and capital needs risks that could affect cash collections, profitability, and future growth.
Pertento Partners LLP and Eduardo Marques filed an amended Schedule 13G reporting passive ownership in Nutex Health, Inc. common stock. As of 12/31/2025, they beneficially owned 324,422 shares, representing 4.6% of the outstanding common stock, with shared voting and dispositive power.
All reported shares are directly owned by advisory clients of Pertento Partners, and no individual client is described as holding more than 5% of the class. The filers state the holdings were not acquired to change or influence control of Nutex Health.